Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab (NCT06211036)

🧪 Interventions in This Study

• Tarlatamab (DRUG)
• Durvalumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (219 Sites)

Showing the first 25 of 219 sites.

• Infirmary Cancer Center — Mobile, Alabama
• University of Southern California — Los Angeles, California
• Yale New Haven Hospital — New Haven, Connecticut
• University Cancer and Blood Center LLC — Athens, Georgia
• Emory University — Atlanta, Georgia
• Northeast Georgia Medical Center — Gainesville, Georgia
• University of Illinois Chicago — Chicago, Illinois
• Franciscan Health Indianapolis — Indianapolis, Indiana
• Our Lady of the Lake Cancer Institute — Baton Rouge, Louisiana
• Dana-Farber Cancer Institute — Boston, Massachusetts
• Cancer and Hematology Centers of Western Michigan — Grand Rapids, Michigan
• Mayo Clinic — Rochester, Minnesota
• Allina Health System dba Allina Health Cancer Institute — Saint Paul, Minnesota
• Oncology Hematology Associates — Springfield, Missouri
• Nebraska Cancer Specialists — Omaha, Nebraska
• Astera Cancer Care — East Brunswick, New Jersey
• Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
• Montefiore Medical Center - Bronx — The Bronx, New York
• Duke University — Durham, North Carolina
• Wake Forest University Health Sciences — Winston-Salem, North Carolina
• Oncology Hematology Care Incorporated — Cincinnati, Ohio
• University Hospitals Cleveland Medical Center — Cleveland, Ohio
• The Ohio State University — Columbus, Ohio
• Oncology Associates of Oregon, PC — Eugene, Oregon
• Oregon Health and Science University — Portland, Oregon

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Extensive-Stage Small-Cell Lung Cancer

• Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) — Springdale, Arkansas
• Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy — Anchorage, Alaska
• MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer — Washington D.C., District of Columbia
• A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC — Los Angeles, California
• Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer — Tucson, Arizona

Explore by condition: All Extensive-Stage Small-Cell Lung Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.